Document is current
Any future updates will be listed below
-
Authors
Dixon-Douglas, Julia
Virassamy, Balaji https://orcid.org/0000-0002-7341-8104
Clarke, Kylie
Hun, Michael
Luen, Stephen J.
Savas, Peter https://orcid.org/0000-0001-5999-428X
van Geelen, Courtney T. https://orcid.org/0000-0002-2716-9135
David, Steven
Francis, Prudence A. https://orcid.org/0000-0002-7207-9286
Salgado, Roberto https://orcid.org/0000-0002-1110-3801
Michiels, Stefan https://orcid.org/0000-0002-6963-2968
Loi, Sherene https://orcid.org/0000-0001-6137-9171
-
Funding
Funding for this research was provided by:
Breast Cancer Trials Australia and New Zealand
- License Information
-
More Information
Article History
Received: 26 March 2024
Accepted: 19 September 2024
First Online: 21 October 2024
Competing interests
: J.D.D. has received travel and accommodation support for conferences from Novartis, MSD and Pierre Fabre and has received an honorarium from Gilead Life Sciences. S.L. receives research funding to institution from Novartis, Bristol Myers Squibb, MSD, Eli Lilly, Nektar Therapeutics, AstraZeneca/Daiichi Sankyo and Seattle Genetics. S.L. has acted as consultant to Seattle Genetics, Novartis, Bristol Myers Squibb, MSD, AstraZeneca/Daiichi Sankyo, Eli Lilly, Pfizer, Gilead Therapeutics, and Roche-Genentech. S.L. has acted as consultant or advisory board to Novartis, GlaxoSmithKline, Roche-Genentech, AstraZeneca/Daiichi Sankyo, Gilead Sciences, Seattle Genetics, MSD, Eli Lilly and Bristol Myers Squibb. S.J.L. receives research funding to institution from AstraZeneca, Beigene, Novartis, Roche, and SpringWorks Therapeutics. R.S. has served on advisory board and provided lectures for BMS, Roche, Exact Sciences, Daichii Sankyo and AstraZeneca and has received institutional research funding from Roche, Puma and MSD. P.F. has received an honorarium from Eli Lilly and Amplity Health.
